Negative / Null Result ReportMedicine
Leukel C, Loibl K, Leuders T · 2024 · Trends in neuroscience and education
Background Problem-solving and learning in mathematics involves sensory perception and processing. Multisensory integration may contribute by enhancing sensory estimates. This study aims to assess if combining visual and somatosensory…
View details →DOI: 10.1016/j.tine.2024.100238 Negative / Null Result ReportOpen accessMedicine
Struyf S, Koster EHW, Van Beveren ML et al. · 2026 · Psychologica Belgica
Introduction Emotion regulation (ER) plays a crucial role in children and adolescents' emotional well-being. However, the use of adaptive strategies often remains challenging during early adolescence, partly because cognitive functions…
View details →DOI: 10.5334/pb.1399 Negative / Null Result ReportMedicine
Lindelien CM, Xu X, Knox AS et al. · 2024 · Bulletin of environmental contamination and toxicology
Long-term metal remediation in wetland treatment systems (WTSs) involves facilitating dissimilatory sulfate reduction to produce sulfide and mineralize metals in deep sediments. We evaluated seasonal sulfur cycling in two constructed…
View details →DOI: 10.1007/s00128-024-03942-6 Methods Dead-EndOpen accessMedicine
Haslam A, Olivier T, Prasad V · 2023 · ESMO open
Background The statistical plan of a phase II trial should balance minimizing the premature termination of potentially beneficial therapies (i.e. false negatives) and the further, costly testing of ineffective drugs (i.e. false positives).…
View details →DOI: 10.1016/j.esmoop.2022.100779 Negative / Null Result ReportMedicine
Kircik L, Tsianakas A, Valenzuela F et al. · 2025 · The British journal of dermatology
Background Atopic dermatitis (AD), the most common inflammatory skin disorder, carries a significant public health burden. Many patients with moderate-to-severe AD are unable to achieve adequate disease control with topical treatment and…
View details →DOI: 10.1093/bjd/ljaf156 Negative / Null Result ReportMedicine
Roupret M, Bertaut A, Pignot G et al. · 2026 · Annals of oncology : official journal of the European Society for Medical Oncology
Background Standard treatment of high-risk non-muscle-invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor is intravesical instillation with Bacillus Calmette-Guérin (BCG) (induction and maintenance regimens);…
View details →DOI: 10.1016/j.annonc.2025.09.017 Negative / Null Result ReportMedicine
Falkenhorst J, Ivanyi P, Schulz T et al. · 2025 · Clinical cancer research : an official journal of the American Association for Cancer Research
Purpose Imatinib resistance is conferred by secondary mutations within the ATP-binding pocket or the activation loop of KIT in gastrointestinal stromal tumors (GIST). Ponatinib is active against KIT secondary activation loop and the…
View details →DOI: 10.1158/1078-0432.ccr-25-0222 Negative / Null Result ReportOpen accessMedicine
Sahebjam S, Bazer DA, Rhun EL et al. · 2026 · Neuro-oncology advances
Background Abemaciclib is a selective cyclin-dependent kinase 4 and 6 inhibitor that penetrates the blood-brain barrier, resulting in comparable concentrations in tissue and plasma. The primary objective of this nonrandomized Simon…
View details →DOI: 10.1093/noajnl/vdag005 Negative / Null Result ReportOpen accessMedicine
Kim DW, Kim RD, Jimenez MM et al. · 2025 · The oncologist
Background Ramucirumab plus paclitaxel after progression on fluoropyrimidine/platinum in metastatic gastric (GA) and gastroesophageal junction adenocarcinoma (GEJC) has shown improvement in overall survival over paclitaxel alone. However,…
View details →DOI: 10.1093/oncolo/oyaf303 Negative / Null Result ReportOpen accessMedicine
Leelahawong P, Ketsuwan C · 2026 · Journal of clinical medicine
Background/Objectives : To evaluate whether adjunctive silodosin improves the stone-free rate (SFR) and clinical outcomes of extracorporeal shock wave lithotripsy (ESWL) for renal calculi. Methods : In this prospective randomised…
View details →DOI: 10.3390/jcm15072471 Negative / Null Result ReportOpen accessMedicine
Chibaudel B, Dourthe LM, André T et al. · 2026 · Signal transduction and targeted therapy
Managing unresectable metastatic colorectal cancer (mCRC) requires a comprehensive strategy. While chemotherapy, anti-angiogenic, and anti-epidermal growth factor receptor (EGFR) agents are available, strategy trials are needed to optimize…
View details →DOI: 10.1038/s41392-026-02639-y Negative / Null Result ReportOpen accessMedicine
Wheless MC, Stockton S, Soares HP et al. · 2025 · The oncologist
Background Mutations in TP53 are common in gastroesophageal cancer and portend a poor prognosis. Tumor cells with TP53 mutations increasingly rely on ataxia-telangiectasia and Rad3-related (ATR) protein to respond to and repair DNA damage…
View details →DOI: 10.1093/oncolo/oyaf400 Negative / Null Result ReportOpen accessMedicine
Nagatani Y, Kiyota N, Yamazaki T et al. · 2026 · Japanese journal of clinical oncology
Background Salivary gland cancer (SGC) is rare and has various histological types. This rarity and heterogeneity have hindered elucidation of the therapeutic contribution of systemic therapy, including immune checkpoint inhibitors, to…
View details →DOI: 10.1093/jjco/hyaf192 Failed Experiment ReportOpen accessMedicine
Cree BAC, Freedman MS, Gold M et al. · 2025 · Annals of neurology
Objective Elezanumab is a monoclonal antibody that binds repulsive guidance molecule a (RGMa), an inhibitor of central nervous system regeneration after inflammation or injury. The aim was to assess the safety and efficacy of elezanumab in…
View details →DOI: 10.1002/ana.27262 Failed Experiment ReportMedicine
Lee JM, Miller A, Rose PG et al. · 2025 · Clinical cancer research : an official journal of the American Association for Cancer Research
Purpose We assessed the efficacy of anti-PD-L1 durvalumab in combination with olaparib and cediranib (DOC), compared with the standard-of-care chemotherapy (SOC) in patients with platinum-resistant ovarian cancer (PROC), who had prior…
View details →DOI: 10.1158/1078-0432.ccr-24-3877 Negative / Null Result ReportMedicine
Gong J, Mita AC, Wei Z et al. · 2024 · JCO precision oncology
Purpose Despite fibroblast growth factor receptor ( FGFR ) inhibitors being approved in tumor types with select FGFR rearrangements or gene mutations, amplifications of FGFR represent the most common FGFR alteration across malignancies.…
View details →DOI: 10.1200/po.23.00406 Negative / Null Result ReportOpen accessMedicine
King B, Mesinkovska N, Senna M et al. · 2025 · Journal of the European Academy of Dermatology and Venereology : JEADV
Background Etrasimod, an oral, selective sphingosine 1-phosphate 1, 4 and 5 receptor modulator approved for the treatment of ulcerative colitis, has been studied in immune-mediated inflammatory diseases, including alopecia areata (AA).…
View details →DOI: 10.1111/jdv.20605 Negative / Null Result ReportMedicine
Schulte B, Mohindra N, Milhem M et al. · 2021 · British journal of cancer
Background Pazopanib is active in refractory soft-tissue sarcoma (STS) and significantly prolongs PFS. Prior studies of combinations of metronomic topotecan with pazopanib have indicated preclinical evidence of response in patients with…
View details →DOI: 10.1038/s41416-021-01448-0 Negative / Null Result ReportOpen accessMedicine
Thavaneswaran S, Lin F, Espinoza D et al. · 2025 · NPJ precision oncology
This single-arm phase II trial (ACTRN12620000918921) evaluated the clinical activity of tremelimumab (10 mg/kg intravenously every 4 weeks for 6 cycles) in advanced cancers with a high tumour mutational burden (TMB), defined as TMB > 10…
View details →DOI: 10.1038/s41698-025-01156-5 Negative / Null Result ReportOpen accessMedicine
Hsu YC, Lin PT, Teng W et al. · 2024 · Cancers
Background The combination of anti-angiogenic therapy and immune checkpoint inhibitors has revolutionized the management of unresectable hepatocellular carcinoma (uHCC). While an early-phase study demonstrated promising outcomes for…
View details →DOI: 10.3390/cancers16203458 Negative / Null Result ReportMedicine
Harada H, Omori S, Mori K et al. · 2022 · International journal of clinical oncology
Background This multi-institutional clinical trial evaluated the feasibility of intensity-modulated radiotherapy (IMRT) for patients with locally advanced non-small cell lung cancer (NSCLC). Methods The major inclusion criteria were…
View details →DOI: 10.1007/s10147-022-02151-7 Failed Experiment ReportMedicine
Andres S, Finch L, Iasonos A et al. · 2024 · Gynecologic oncology
Objective To determine the safety and efficacy of the oral progesterone antagonist onapristone extended release (onapristone-XR) in patients with recurrent progesterone receptor (PR)-positive adult-type granulosa cell tumor (aGCT),…
View details →DOI: 10.1016/j.ygyno.2024.06.026 Negative / Null Result ReportOpen accessMedicine
Levy A, Morel D, Texier M et al. · 2025 · Signal transduction and targeted therapy
Immunoradiotherapy holds promise for improving outcomes in patients with advanced solid tumors, including in soft-tissue sarcoma (STS). However, the ideal combination of treatment modalities remains to be determined, and reliable…
View details →DOI: 10.1038/s41392-025-02173-3 Negative / Null Result ReportOpen accessMedicine
Lenz HJ, Parikh A, Spigel DR et al. · 2024 · Journal for immunotherapy of cancer
Background Standard first-line therapies for metastatic colorectal cancer (mCRC) include fluoropyrimidine-containing regimens with oxaliplatin and/or irinotecan and a biologic agent. Immunotherapy may enhance antitumor activity in…
View details →DOI: 10.1136/jitc-2023-008409 Negative / Null Result ReportOpen accessMedicine
Pravisano F, Costa J, Marchi L et al. · 2026 · Cancers
The role of adjuvant therapy in stage III melanoma is well established in clinical practice. Because stage IIB-IIC melanoma carries a risk of recurrence and melanoma-specific mortality comparable to that of stage III disease, adjuvant…
View details →DOI: 10.3390/cancers18111802 Negative / Null Result ReportMedicine
Agnihotri G, Lio PA · 2020 · Clinical drug investigation
Multiple pathways contribute to the pathogenesis of atopic dermatitis (AD), and various targeted topical, biologic, and oral systemic agents have subsequently been developed. This review examines the mechanism of action and study designs…
View details →DOI: 10.1007/s40261-020-00905-7 Negative / Null Result ReportOpen accessMedicine
Geurts VCM, Voorwerk L, Balduzzi S et al. · 2023 · Breast (Edinburgh, Scotland)
The large majority of patients with HER2-positive metastatic breast cancer (MBC) will eventually develop resistance to anti-HER2 therapy and die of this disease. Despite, relatively high levels of stromal tumor infiltrating lymphocytes…
View details →DOI: 10.1016/j.breast.2023.06.007 Failed Experiment ReportOpen accessMedicine
Da Cruz RS, Teague HL, Ramos-Benitez MJ et al. · 2026 · Critical care explorations
Objectives Understanding the mechanistic impact of fostamatinib, a spleen tyrosine kinase inhibitor, in severe COVID-19 using biomarkers associated with disease severity is crucial for the development of host-directed therapeutics. We…
View details →DOI: 10.1097/cce.0000000000001405 Failed Experiment ReportMedicine
Ishikawa M, Shibata T, Iwata T et al. · 2021 · Gynecologic oncology
Objective To assess the efficacy and safety of dose-dense weekly paclitaxel plus carboplatin (ddTC) with or without bevacizumab compared to conventional, tri-weekly paclitaxel plus carboplatin (cTC) with or without bevacizumab, in…
View details →DOI: 10.1016/j.ygyno.2021.05.007 Failed Experiment ReportOpen accessMedicine
Juárez-García M, Plasencia-Rodríguez C, Benavent D et al. · 2026 · Therapeutic advances in musculoskeletal disease
Background Axial spondyloarthritis (axSpA) is an inflammatory disease in which, despite expanding therapeutic options, a substantial proportion of patients do not achieve the desired treatment target, highlighting the emerging concept of…
View details →DOI: 10.1177/1759720x261456162 